Adagene (ADAG) vs Spruce Biosciences (SPRB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Adagene (ADAG) has outperformed Spruce Biosciences (SPRB) over the past year, losing 2.2% versus a loss of 63.8%. Over five years, ADAG leads with a -79.7% price change compared with -99.8% for SPRB. Adagene is the larger company by market cap ($118.2 million vs $109.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ADAG | SPRB |
|---|---|---|
| Share price | $1.76 | $38.00 |
| Market cap | $118.17M | $109.21M |
| 1-day change | -12.44% | -6.15% |
| YTD return | -6.88% | -56.38% |
| 1-year return | -2.22% | -63.81% |
| 5-year return | -79.75% | -99.75% |
| Forward P/E | — | 11.79 |
| EPS (TTM) | $-0.37 | $-33.29 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $7.67M | $0 |
| Revenue growth (YoY) | +7332.76% | -100.00% |
| Net income (latest FY) | $-17.61M | $-38.97M |
| Operating margin | -279.48% | — |
| Net margin | -229.56% | — |
| 52-week high | $4.85 | $111.00 |
| 52-week low | $1.27 | $38.00 |
| Distance from 52-week high | -63.71% | -65.77% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +463.07% | +288.00% |
| Average volume | 348.81K | 89.33K |
| Shares outstanding | 67.14M | 2.87M |
| Employees | 128 | 25 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ADAG has outperformed SPRB by 61.6 percentage points over the past year.
- Adagene grew revenue faster in its latest fiscal year (+7332.76% vs -100.00%).
About Adagene
ADAG stock →Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 128 employees
About Spruce Biosciences
SPRB stock →Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders.
Health Care · Biotechnology: Pharmaceutical Preparations · 25 employees
ADAG vs SPRB FAQ
Which is bigger, Adagene or Spruce Biosciences?
Adagene (ADAG) is larger, with a market capitalization of $118.17M compared with $109.21M for Spruce Biosciences (SPRB).
Which stock has performed better over the past year, ADAG or SPRB?
ADAG returned -2.22% over the past 12 months, compared with -63.81% for SPRB (price return, excluding dividends). Past performance does not predict future results.
Are Adagene and Spruce Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.